- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Reports: ESI may start 'price war' over new hepatitis C drugs
- FDA issues sweeping new requirements for long-acting opioids
- FDA approves Bayer's Nexavar for thyroid cancer
- FDA approves Jubilant Life Sciences' quetiapine fumarate tablets
BALTIMORE — The Food and Drug Administration has approved a generic heart disease drug made by Lupin, the Indian drug maker said.
Lupin said the FDA approved its ranolazine extended-release tablets in the 500-mg and 1,000-mg strengths. The drug is used to treat chronic angina.
Ranolazine extended-release tablets are a generic version of Gilead Sciences' Ranexa, which had sales of about $443.4 million during the 12-month period that ended in March, according to IMS Health.